Basic Neurosciences · Paper A
Acetylcholine metabolism
Two major drug classes hijack the same enzyme step in opposite directions, and that single fact explains both a dementia treatment and a poisoning antidote. Acetylcholine is made, released, and broken down through a fixed synthesis-to-breakdown cycle, so a drug that blocks the breakdown step boosts the transmitter without adding any new supply. In Alzheimer's disease, e.g. with donepezil, slowing that breakdown step raises brain acetylcholine levels enough to help memory.
Acetylcholine is made in nerve terminals by the enzyme choline acetyltransferase (ChAT), the specific marker enzyme for cholinergic neurons. Choline is recycled from the synapseThe tiny gap between two nerve cells where a chemical signal passes from one to the other.Read more → by a transporter called CHT1. Newly made acetylcholine is packaged into vesicles and released by calcium-dependent exocytosis. Synaptic action ends mainly through acetylcholinesterase, which breaks acetylcholine down into choline and acetate. Cholinesterase inhibitors, such as donepezil, slow this breakdown to partially compensate for cholinergic neuron loss in Alzheimer's disease. Organophosphates, by contrast, irreversibly block acetylcholinesterase, causing a dangerous cholinergic toxidrome treated with atropine. A farm worker exposed to an organophosphate pesticide, e.g. a common agricultural insecticide, develops excessive salivation and a slow heart rate, and atropine must be given urgently to block the resulting acetylcholine excess.
A fresh doctor might think of acetylcholine as just "the memory ." What actually matters clinically is the SINGLE enzyme step that ends its action, because two entirely different drug classes both act at that one step, one therapeutically and one lethally. Hold the phrase ONE ENZYME, TWO DIRECTIONS through every section below.
Acetylcholine is a (a chemical messenger released by nerve cells to communicate with muscles, glands, and other neurons) used throughout the peripheral nervous system and in specific brain pathways involved in memory and attention. Its life cycle has four steps: synthesis, packaging, release, and breakdown, and the breakdown step is where most clinically important drugs intervene.
A common mistake is assuming pralidoxime (an antidote that reactivates acetylcholinesterase) always works if given eventually. Organophosphate binding to the enzyme can "age", undergo a chemical change (dealkylation) that makes the block permanent, after which pralidoxime can no longer reactivate the enzyme. This is why early treatment, ideally within hours of exposure, matters far more for organophosphate poisoning than for most other toxidromes, and why atropine, which blocks the downstream muscarinic effects rather than the enzyme itself, remains useful even after ageing has occurred.
Acetylcholine is synthesised in the nerve terminal from choline and acetyl-CoA (an energy-carrying molecule from cell metabolism) by the enzyme choline acetyltransferase (ChAT), which is used as a specific marker for cholinergic neurons on staining. The finished transmitter is packaged into vesicles by the vesicular acetylcholine transporter (VAChT) and released into the synaptic cleft (the gap between two neurons) by calcium-dependent exocytosis when an arrives. Choline itself is recycled back into the terminal afterward by a dedicated transporter, CHT1, for reuse in the next round of synthesis.
Once released, acetylcholine's action ends mainly through acetylcholinesterase, an enzyme that rapidly hydrolyses (breaks down) it into choline and acetate. In Alzheimer's disease, cholinergic neurons in the nucleus basalis of Meynert (a small forebrain structure that supplies most of the cortex with acetylcholine) degenerate, so brain acetylcholine levels fall. Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) slow the breakdown step, e.g. keeping more acetylcholine available in the for longer, and this partially compensates for the reduced supply, improving cognition modestly rather than reversing the underlying degeneration.
Organophosphates (a class of pesticides and, historically, nerve agents) also block acetylcholinesterase, but irreversibly rather than the reversible blockade of donepezil-type drugs. This produces a cholinergic toxidrome (a recognisable pattern of poisoning) with excessive salivation, lacrimation, urination, defecation, gastrointestinal upset, and emesis, often remembered with the mnemonic SLUDGE, plus bradycardia (slow heart rate) and miosis (constricted pupils) from muscarinic overactivity, alongside muscle fasciculations and weakness from nicotinic overactivity. A farm worker exposed to an organophosphate insecticide who develops excessive salivation and a slow heart rate is showing this exact toxidrome.
Acetylcholinesterase should not be confused with butyrylcholinesterase, a related but lower- plasma and glial enzyme that hydrolyses esters more broadly and is not the primary site of physiological neurotransmission termination. Choline acetyltransferase (ChAT), the synthesis enzyme, should not be confused with choline kinase, a completely different enzyme that phosphorylates choline toward membrane phospholipid synthesis rather than production. Reversible cholinesterase inhibitors used therapeutically should not be confused with the irreversible organophosphate block seen in poisoning, since the clinical direction, helping cognition versus causing a toxic emergency, is opposite despite both acting on the same enzyme.
Diagnosis of Alzheimer's disease rests on clinical assessment and cognitive screening (structured tools such as the or the ), with imaging used mainly to exclude other reversible causes of decline, rather than on any single acetylcholine-related biomarker test. Diagnosis of suspected organophosphate poisoning, by contrast, is primarily clinical, made from the SLUDGE toxidrome plus a history of pesticide or nerve-agent exposure, but investigation includes measuring plasma or red-cell cholinesterase activity to confirm exposure and monitor recovery over time: a falling activity level confirms ongoing , and a rising one tracks resolution.
Cholinesterase inhibitors are first-line pharmacological treatment for mild-to-moderate Alzheimer's disease under NICE dementia guidance, alongside non-pharmacological support such as structured activity and carer education. Organophosphate poisoning is managed as a medical emergency with atropine titrated against secretions and heart rate, alongside pralidoxime given as early as possible, ideally before the ageing reaction sets in, following standard toxicology and emergency medicine protocols; supportive airway management and decontamination (removing contaminated clothing, washing exposed skin) are also first-line steps.
The high-yield pearl: once ageing has occurred, pralidoxime cannot help: atropine becomes the mainstay regardless of how much is given. Vignettes often describe a poisoning case treated hours after exposure and expect recognition that pralidoxime may no longer help once ageing has occurred, so atropine alone becomes the mainstay. Another trap contrasts donepezil's reversible mechanism with an organophosphate's irreversible one and expects the candidate to explain why the therapeutic drug is safe for chronic use while the poison is not. A further trap asks which enzyme, ChAT or acetylcholinesterase, is the marker of cholinergic neurons: it is ChAT, the synthesis enzyme, not the breakdown enzyme.
Acetylcholine is synthesised by ChAT from choline and acetyl-CoA, packaged by VAChT, released by calcium-dependent exocytosis, and its action is ended by acetylcholinesterase. Cholinesterase inhibitors slow that breakdown step reversibly to treat Alzheimer's disease, diagnosed clinically and with cognitive screening, following degeneration of the nucleus basalis of Meynert, while organophosphates block the same enzyme irreversibly, causing a SLUDGE-pattern cholinergic toxidrome diagnosed from exposure history and cholinesterase activity, and treated urgently with atropine and, before ageing occurs, pralidoxime.